Clinical Trial

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Study acronym: REDUCE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, prospective, non-randomized, single-arm, multicentric study to evaluate the activity and safety of treatment with 4 cycles (instead of 6) of chemotherapy (platinum (cisplatin or carboplatin) and 5-Fluorouracil) in combination with pembrolizumab for the first-line treatment of CPS PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma. A total of 86 patients will have to be enrolled in this study.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-08-14; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2024-10-24
Trial Details
NCT Number NCT06557889
Lead Sponsor Institut Claudius Regaud
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 86 participants
Start Date 2024-10-21
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-11